Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 5,056 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Bipolar Depression
Interventions: Escitalopram, Celecoxib, Placebo; Drug
Lead sponsor: Loyola University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Bladder Cancer, Bladder Tumor, Urothelial Carcinoma
Interventions: Sulforaphane Administration, Placebo Administration, Standard of Care Surgery; Drug · Other · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Tampa, Florida

Conditions: Alcohol Use Disorder
Interventions: Acamprosate calcium, Placebo; Drug · Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Inflammation, Dyslipidemia
Interventions: Fish oil, Krill oil; Dietary Supplement
Lead sponsor: Tufts University; Other
Eligibility: 50 Years to 75 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Failure
Interventions: LCP-Tacro, Tacrolimus -IR; Drug
Lead sponsor: Veloxis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Chicago, Illinois • St Louis, Missouri • Philadelphia, Pennsylvania

Conditions: Type 2 Diabetes Mellitus
Interventions: Sitagliptin, Placebo, Neuropeptide Y, Enalaprilat, Valsartan 160mg; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cholesterol, Triglycerides, Omega-3, Eicosapentaenoic Acid
Interventions: AlmegaPL (FDA NDIN # 826); Dietary Supplement
Lead sponsor: Qualitas Health; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Tempe, Arizona • Houston, Texas

Conditions: Gout, Hyperuricemia
Interventions: LC350189 200 mg; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy
Interventions: Omeprazole, Lactobacillus rhamnosus GG, Placebo; Drug · Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pancreatic Cancer
Interventions: MKC-1; Drug
Lead sponsor: CASI pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Glioblastoma Multiforme
Interventions: XL184; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 5 more

Conditions: HIV Infections, Hepatitis C, Liver Disease
Interventions: Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 36
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more

Conditions: Melanoma
Interventions: Pembrolizumab, Vibostolimab, Pembrolizumab/Quavonlimab, Lenvatinib, Favezelimab/Pembrolizumab, ATRA; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 15
States / cities: Los Angeles, California • Santa Monica, California • Aurora, Colorado + 11 more

Conditions: Total Knee Arthroplasty, Opioid Use
Interventions: Dronabinol 5mg Cap, Placebo oral tablet; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 70 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Human Immunodeficiency Virus Infection
Interventions: rice bran arabinoxylan compound (RBAC), Placebo; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Adverse Effects
Interventions: Frozen capsule, Capsule with food, Capsule without food, Capsule with milk; Dietary Supplement
Lead sponsor: University of Mississippi, Oxford; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: AZD4635, Oleclumab, Durvalumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 9
States / cities: Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 6 more

Conditions: Peripheral Arterial Disease
Interventions: Pro-Omega, Pro-Omega Placebo; Dietary Supplement · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Breast Cancer
Interventions: Sapanisertib, Fulvestrant, Exemestane; Drug
Lead sponsor: Calithera Biosciences, Inc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Los Angeles, California • San Francisco, California • Santa Barbara, California + 24 more

Conditions: Marijuana Dependence
Interventions: Vilazodone, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Diabetic Macular Edema
Interventions: Dextromethorphan hydrobromide; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: High Grade Glioma
Interventions: Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy; Procedure · Drug · Radiation
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Solid Tumors, Advanced Cancer, Renal Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, NSCLC, Lung Cancer, Brain Tumor, Glioblastoma Multiforme, EGFR Gene Mutation, MET Amplification, HGF, Thyroid Cancer, Pancreatic Cancer, Colon Cancer, MET Alteration, MET Fusion, Exon 14 Skipping
Interventions: APL-101 Oral Capsules; Drug
Lead sponsor: Apollomics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more

Conditions: Healthy
Interventions: Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation, Rabeprazole tablet; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Search by objective public record fields.

Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention

Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder

Study Comparing Fish Oil and Krill Oil

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

Effect of DPP4 Inhibition on Vasoconstriction

AlmegaPL CV Health Open Label Study

Renal PK Study of LC350189

A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis

Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Dronabinol in Total Knee Arthroplasty (TKA)

The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV

Method of Fish Oil Administration on Patient Compliance

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Vilazodone Treatment for Marijuana Dependence

Dextromethorphan for Diabetic Macular Edema

STARLITE for Unresectable High-Grade Gliomas

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations